Sinopharm Modern: Net profit of 942 million yuan in 2025, with sales revenue of 4.476 billion yuan in the raw material drugs and pharmaceutical intermediates segment.

On March 27, Guoyao Modern announced its 2025 annual report, with total revenue reaching 9.363 billion yuan, a year-on-year decrease of 14.39%; net profit attributable to shareholders was 942 million yuan, a year-on-year decrease of 13.11%; net profit attributable to shareholders after deducting non-recurring gains and losses was 849 million yuan, a year-on-year decrease of 18.6%; net cash flow from operating activities was 1.698 billion yuan, a year-on-year decrease of 24.73%; EPS (fully diluted) was 0.7021 yuan.

In the fourth quarter, the company reported revenue of 2.44 billion yuan, a year-on-year increase of 4.2%; net profit attributable to shareholders was 140 million yuan, a year-on-year increase of 8.8%; net profit attributable to shareholders after deducting non-recurring gains and losses was 110 million yuan, a year-on-year decrease of 5.6%; EPS was 0.1047 yuan.

In its 2025 annual report, the company mentioned that the sales revenue of its raw materials and pharmaceutical intermediates segment was 4.476 billion yuan, a year-on-year decrease of 13.89%, accounting for 47.81% of total revenue. In this segment, the sales volume of 7-ACA, urine-derived biochemical products, and cefoperazone sodium crude salt performed well, with year-on-year increases of 114.74%, 44.09%, and 43.69%, respectively. However, due to market oversupply, the overall sales prices declined, leading to a 9.15 percentage point decrease in the gross profit margin of the segment.

In the formulation segment, affected by market conditions, sales revenue was 4.622 billion yuan, a year-on-year decrease of 15.21%, accounting for 49.36% of total revenue. Although the company’s cardiovascular drugs such as nifedipine controlled-release tablets saw an increase in sales, revenue from anti-infection formulations and neurological drugs experienced varying degrees of decline, down 17.45% and 18.79% year-on-year, respectively. The overall gross profit margin of the segment decreased by 3.66 percentage points to 42.06%.

In the future, the company will anchor its goals for steady development, vigorously promote innovative breakthroughs, and further deepen brand building. It will continue to focus on integrated synergy and optimization of the industrial chain, enhance the supply chain, strengthen chains, improve chains, and actively expand external development space to accelerate the pace of transformation and upgrading through systematic layout.

(Guoyao Modern Announcement)

(Editor: Yang Yan, Lin Chen)

Keywords:

                                                            Healthcare